Vaxart, Inc. (VXRT), Wednesday announced pre-clinical data showcasing the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination for the treatment of human papillomavirus or HPV-related cervical dysplasia.
According to the study published in Vaccines journal, the vaccine has the ability to stimulate specific T cell immune responses, reduce tumor size, and increase survival rates in mice with HPV-related tumors.
Sean Tucker, Vaxart's Founder and Chief Scientific Officer, said, "... these initial findings suggest that our mucosal vaccine platform could open the door to a non-invasive approach designed to prevent the progression to cervical cancer."
Currently, Vaxart's stock is trading at $0.8643, down 2.7 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.